Healthcare Review: BioScrip Inc, Medivation Inc, Array Biopharma Inc, Celldex Therapeutics, RadNet Inc. Print E-mail
By Staff and Wire Reports   
Friday, 09 May 2014 12:35
U.S. stocks were set for a flat open on Friday, putting the S&P 500 on track to close a week of choppy trading with a slight decline, while the Nasdaq was on pace for its worst weekly decline in four. Shares of BioScrip Inc. ($BIOS) are trading 9.85% higher at $6.69. Yesterday, the company announced 2014 first quarter financial results. First quarter revenue from continuing operations was $239.6 million and the net loss from continuing operations was $25.4 million, or $0.37 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.13.

Medivation Inc ($MDVN)’s shares jumped 7.72% to $64.63 after the company yesterday reported Q1 EPS of ($0.18), $0.09 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $95.7 million versus the consensus estimate of $94.64 million.

Array Biopharma Inc (ARRY)’s shares soared 7.81% to $3.93. Recently, the company announced that as part of its continued evolution toward late-stage development and commercialization, Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati Therapeutics, joined the company's board of directors, effective April 25, 2014.

Celldex Therapeutics, Inc. ($CLDX)’s shares added 9.08% to $12.10. Celldex Therapeutics, Inc. (Celldex), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.

RadNet Inc. (NASDAQ:RDNT)’s shares gained 14.10% to $6.07. The company reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $168.9 million versus the consensus estimate of $173.53 million.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus